Metabolic aspects of oryzanol in rats by Gillespie, Michelle Smith
Louisiana State University
LSU Digital Commons
LSU Master's Theses Graduate School
2003
Metabolic aspects of oryzanol in rats
Michelle Smith Gillespie
Louisiana State University and Agricultural and Mechanical College, mgilles@lsu.edu
Follow this and additional works at: https://digitalcommons.lsu.edu/gradschool_theses
Part of the Human Ecology Commons
This Thesis is brought to you for free and open access by the Graduate School at LSU Digital Commons. It has been accepted for inclusion in LSU
Master's Theses by an authorized graduate school editor of LSU Digital Commons. For more information, please contact gradetd@lsu.edu.
Recommended Citation
Gillespie, Michelle Smith, "Metabolic aspects of oryzanol in rats" (2003). LSU Master's Theses. 4129.
https://digitalcommons.lsu.edu/gradschool_theses/4129
 
 
 
 
METABOLIC ASPECTS OF ORYZANOL IN RATS 
 
 
 
 
 
 
 
 
A Thesis 
 
Submitted to the Graduate Faculty of the  
Louisiana State University and  
Agricultural and Mechanical College 
in partial fulfillment of 
the requirements for the degree of 
Master of Science 
 
in  
 
The School of Human Ecology 
 
 
 
 
 
 
 
 
by 
Michelle Smith Gillespie 
B.S., Louisiana State University, 1991 
May 2003 
 ii 
 
DEDICATION 
This manual is dedicated with love to my dearest friend and husband, Jeffrey 
Morris Gillespie, who has selflessly supported me through my graduate studies. 
 iii 
ACKNOWLEDGMENTS 
I would like to express my deep appreciation to Dr. Maren Hegsted who served as 
one of my major professors on this project.  She is an excellent mentor for whom my 
respect has grown tremendously over the past semesters.  It was a blessing to have had 
the opportunity to work with such an amazing woman.  She has a remarkable ability to 
get things done while never compromising time to sit and talk with her students.  I would 
like to thank Dr. J. Samuel Godber who also served as a major professor.  Many long 
discussions in his office inevitably led to a few answers, several questions, and a new 
perspective on life in general.  His ideas and philosophies are always thought provoking.  
A sincere expression of gratitude goes to Dr. Michael Keenan, a committee member 
whose curiosity and enthusiasm regarding the field of nutrition is absolutely contagious.  
His level of concern for the well-being of his students and colleagues is extraordinary.  
Also, I would like to thank Dr. Zhimin Xu who was always around to answer my 
incessant questions.  His energy, quick smile, and frequent encouragement was very 
much appreciated.  The expertise and knowledge of instrumentation that he brought to the 
table was indispensable.  Finally, Mary C. May, Heather C. Colona, Kathy McCutcheon, 
and Anne Francis are recognized for caring for the animals in this experiment.    
 iv 
TABLE OF CONTENTS 
 
DEDICATION………………..……………………………………...……………………ii 
 
ACKNOWLEDGEMENTS…...…………………………………………..……………...iii 
 
LIST OF TABLES…………………………………………………………………….…vii 
 
LIST OF FIGURES……………………………………………………………………..viii 
 
ABSTRACT………………………………………………………………………….…..ix 
 
CHAPTER 1  INTRODUCTION…...……………………………………………...……..1 
 
CHAPTER 2  REVIEW OF LITERATURE…………………………………………...…5 
Rice Bran Improves Cholesterol Levels ………………..…………………………….5 
Animal Studies ……………………………………….……………………...……5 
Human Studies ……………………………………….………………..…….……8 
Oil Fraction of Rice Bran Is Responsible for Improving Cholesterol Levels …..…...10 
Animal Studies ……………………………………….……………………….…10 
Human Studies ……………………………………….…………………….……12 
Unsaponifiable Fraction of Rice Bran Oil Is Capable of Hypolipidemic Action……13 
Animal Studies ……………………………………….………………..…….…..13 
Human Studies ……………………………………….……………………...…..14 
Oryzanol in Unsaponifiable Fraction of Rice Bran Oil Is an Active Hypolipi- 
demic Ingredient …………………………………………………………………….15 
Animal Studies ……………………………………….………………………….15 
Human Studies ……………………………………….………………………….18 
Absorption of Oryzanol …………………………….……………………...……18 
Measurement of Absorption of Oryzanol in Liver ….………………………..…19 
Summary………………………………………………………………………...…...20 
 
CHAPTER 3  METHODS………………………………………………………….……22 
Animals and Diets ………………………………………………………….………..22 
Data Collection ………………………………………………………………...……24 
Fecal Analysis ………………………………………………………………….……25 
Serum Analysis ……………………………………………………………..….……26 
Cholesterol Quantification Using Enzymatic Colorimetric Assay..………….….26 
Oryzanol Detection Using GCMS…………………………………………….....27 
Cholesterol Quantification Using GCMS………………………………………..28 
Hexane Extraction……………………………………………………………28 
Chloroform:Methanol Extraction……………….……………………………29 
Standard Curve……………………………………………………………….30 
Liver Analysis ……………………………………………………………………….30 
Developing Methodology for Oryzanol Quantification……...…………………..30 
HPLC Analysis…………………………………………………………………..32 
 v 
GCMS Analysis……………………………………………………………….....33 
Oil Analysis ……..…………………………………………………………………..33 
Statistical Analys is …………………………………………………………………..34 
Human Pilot Study …………………………………………………………………..34 
HPLC Analysis of Serum for Oryzanol Detection………..….………………….35 
Serum Cholesterol…………………………………………….………………….36 
 
CHAPTER 4  RESULTS AND DISCUSSION……...……….………………………….37 
Weight Gain, Final Weight, and Liver Weight……………………...……………….37 
Balance Study……………………………………………………...……………...…38 
Feed Intake……………………………………………………………………….38 
Oryzanol Intake ………………………………………………………………….40 
Oryzanol Recovery …………………………………………………………...…41 
 Rice Bran Oil and Corn Oil Analysis……………………………………………43 
Serum Cholesterol……………….…………………………...…………………....…44 
Enzymatic Colorimetric Assay……………………..……………………………44 
 GCMS ……………….………………………..….………………………...……47 
Hexane Extraction …………………….…………………………………….47 
Chloroform:Methanol Extraction ………………………….………………..47 
Oryzanol in Serum ……………………………………………………..……………48 
Oryzanol in Liver …………………………………………………………..………..48 
Fate of Dietary Oryzanol………………………………………………………..…...49 
Mode of Action of Oryzanol as Hypolipidemic Agent……………….……….……..51 
Conclusions…………………………………………………………………………..53 
Future Directions …………………………………………………………………....54 
 
REFERENCES….……………………………………………………………………….56 
 
APPENDIX 
A  FORMULAS …………………………………………………………………61 
  
B  HPLC OF LIVER SAMPLES PERFORMED DURING METHODOLOGY  
DEVELOPMENT………………………………………………………………..63  
 
C  DAILY RICE BRAN OIL INTAKE FOR HUMAN PILOT STUDY ………65 
 
D  MUFFIN RECIPE FOR HUMAN PILOT STUDY....…………………….…66 
 
E  HPLC OF DIET SAMPLES……………………………………………….....67 
 
F  HPLC OF FECAL SAMPLE FROM EACH DIET GROUP……………...…69 
 
G  HPLC OF HUMAN SERUM TO DETECT ORYZANOL…………….…….72 
 
 
 
 vi 
H  HPLC OF LIVER SAMPLE FROM EACH DIET GROUP……………...….74 
 
VITA…………………………………………………………………..…………………77 
 vii 
LIST OF TABLES 
 
1. Diets in grams per kilogram ……...……………..……………………………….23 
 
2. Effect of test diets on total weight gain, final body weight, feed efficiency, and 
liver weight …………………….……………………………………….……….39 
 
3. Feed and oryzanol intake associated with fecal collection periods of oryzanol- fed 
rats ……………………………………………………………………………….40 
 
4. Total weight of dry feces, amount of oryzanol detected in feces, and percentage of 
dietary oryzanol recovered in the feces …………………………………………41 
 
5. Significant effects of test diets on feed intake, oryzanol intake, feces, fecal 
oryzanol and percentage of dietary oryzanol recovered in the feces ……………42 
 
6. Comparison of total cholesterol values by diet group obtained from enzymatic 
colorimetic assay and GCMS using hexane or chloroform:methanol 
extraction…………………………………………………………………………45 
 viii 
LIST OF FIGURES 
1. Cycloartenyl ferulate, a common form of oryzanol……………….……………..19 
2. Cholesterol ……………………………………………………………………....20 
3. Average weekly weight by diet group …………………………………….…….37 
4. Percentage of dietary oryzanol not recovered in the feces by diet group and 
batch………………………………………………………………………….…..44 
 ix 
ABSTRACT 
 Using a rat model, this study compared the bioavailability of three forms of 
oryzanol, a compound extracted from rice bran oil that has been associated with 
improved cholesterol levels.  Various methods of extracting lipids from serum and liver 
were explored to determine oryzanol absorption.  Cholesterol levels were obtained via 
enzymatic colorimetric assay and GCMS. 
 Sprague Dawley retired female breeder rats were sustained for 11 weeks on a 
cholesterol- free diet to which either no oryzanol was added (n = 19) or 2.8 g/kg of 
oryzanol was added as:  7% oryzanol rice bran oil (RO, n = 8), crystalline oryzanol (CO, 
n = 8), or crystalline oryzanol dissolved in tocopherol-stripped corn oil (DO, n = 9).  The 
percentage of dietary oryzanol recovered in the feces of rats fed the CO diet (41.9 ± 2.21, 
mean ± SEM) was significantly higher compared to the RO (28.3 ± 3.54) and DO (27.8 ± 
2.63) groups (P < 0.05), suggesting that bioavailability of crystalline oryzanol is lower 
relative to the oil forms. 
 Oryzanol was not detected during GCMS analysis of serum following hexane 
extraction.  Similarly, hexane extractions of liver analyzed via HPLC and GCMS did no t 
reveal oryzanol.  Hexane may not be an appropriate solvent for extracting oryzanol, or 
perhaps the compound is metabolized prior to its entry into the liver or bloodstream. 
 Although serum cholesterol levels determined by colorimetric enzymatic assay 
did not differ significantly among the groups, levels were highest in the RO group, 
followed in sequence by the DO, CO, and oryzanol- free controls.  It is likely that a 
cholesterol-enriched diet is required for the hypolipidemic effect of oryzanol to be 
realized.  Additionally, it is plausible that the cholesterol values from the oryzanol- fed 
 x 
animals were inflated by phytosterols in the serum.  Hexane extractions of serum 
analyzed via GCMS resulted in unintelligible data, suggesting that hexane is not a 
suitable solvent for the extraction of cholesterol from serum.  Although a 2:1 
chloroform:methanol mixture (Folch et al., 1956) resulted in more uniform values, it 
appeared that the extraction of total cholesterol from lipoproteins was incomplete.  
(Supported by USDA IFAFS 2000-04222) 
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CHAPTER 1 
INTRODUCTION 
Cardiovascular disease is the leading cause of death in the United States and 
currently costs Americans an estimated $351.8 billion per year (American Heart 
Association, 2002).  It is well established that an association exists between cholesterol 
levels and incidence of heart attack.  Low-density lipoprotein (LDL) cholesterol levels of 
130 mg/dL or higher and high-density lipoprotein (HDL) cholesterol levels of 40 mg/dL 
or lower are both considered risk factors for cardiovascular disease in humans.  Of 
Americans aged 20 and older, 48.6% of males and 43.3% of females have LDL levels 
high enough to be considered at risk.  In this same group, 39.0% of males and 14.9% of 
females have HDL levels low enough to be considered at risk.  (American Heart 
Association, 2002.  Data from NHANES III, 1988-94, CDC/NCHS.) 
Much research has been done to identify components of food that positively alter 
cholesterol levels and reduce risk of cardiovascular disease.  Cereal brans, including that 
of rice, have shown promising results.  Consumption of rice bran has significantly 
reduced plasma and liver cholesterol levels in hamsters (Kahlon, Saunders, Chow, Chiu, 
& Betschart, 1990; Kahlon, Chow, Sayre, & Betschart, 1992; Kahlon, Edwards, & Chow, 
1998).  LDL levels have decreased while HDL levels have remained stable in humans fed 
diets containing rice bran (Hegsted, Windhauser, Morris, & Lester, 1993).  In particular, 
the oil extracted from rice bran has shown positive effects on cholesterol levels in both 
animals (Sharma & Rukmini, 1986) and humans (Raghuram, Rao, & Rukmini, 1989). 
Rice bran oil is extracted from the germ and bran layers of brown rice and 
contains both saponifiable and unsaponifiable compounds.  The saponifiable fraction 
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consists primarily of triglycerides.  Smaller amounts of diglycerides, monoglycerides, 
free fatty acids, waxes, glycolipids, and phospholipids are also present (Orthoefer, 1996).  
The most prevalent fatty acids are palmitic, oleic, and linoleic (Wilson, Ausman, Lawton, 
Hegsted, & Nicolosi, 2000).  Compared to other edible oils, rice bran oil has a relatively 
high unsaponifiable fraction of 4.2% (Itoh, Tamura, & Matsumoto, 1973).  The 
unsaponifiable components include phytosterols, tocopherols, tocotrienols, and oryzanol.  
Oryzanol was originally identified as a single compound, however it is now known that 
oryzanol is a group of various triterpene alcohols esterified to ferulic acid (Xu & Godber, 
1999).  
The component of rice bran oil that is responsible for the cholesterol- lowering 
effect is still uncertain.  High levels of serum cholesterol-raising fatty acids in rice bran 
oil compared to other vegetable oils have led researchers to explore the unsaponifiable 
fraction (Wilson et al., 2000).  Despite the apparent inferior fatty acid content of rice bran 
oil, this group reported similar reductions in total cholesterol and LDL levels in monkeys 
consuming diets containing rice bran, canola, and corn oil.  In another study, LDL levels 
dropped and HDL levels were unchanged or increased in rats on diets supplemented with 
the unsaponifiable matter from rice bran oil (Sharma & Rukmini, 1987).  More 
specifically, studies have suggested that oryzanol is primarily responsible for the 
hypolipidemic effects of rice bran oil.  Addition of oryzanol to rat diets containing rice 
bran oil was associated with lower cholesterol levels compared to rat diets containing rice 
bran oil alone (Seetharamaiah & Chandrasekhara, 1989).  Oryzanol administered to 
hyperlipidemic persons resulted in improved cholesterol levels (Yoshino et al., 1989).  
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Medicines current ly available for treatment of hypercholesterolemia include bile 
acid sequestrants and HMG-CoA reductase inhibitors, also known as statins.  Studies 
supporting the idea that oryzanol is an active component of rice bran oil with 
hypolipidemic qualities justify the exploration of pharmaceutical possibilities for this 
compound as well.  Comparing the metabolic aspects of various forms of dietary 
oryzanol in rats may be helpful in elucidating the mechanism by which oryzanol is able 
to lower cholesterol levels, as well as providing insight into an optimal way to package it 
for use as a cholesterol- lowering agent. 
The primary objectives of this study were (1) to determine if crystalline oryzanol 
is as bioavailable as oryzanol in rice bran oil or that dissolved in corn oil, and (2) to 
investigate the relative cholesterol- lowering capabilities of the three forms.  It was 
hypothesized that oryzanol within rice bran oil would be more efficiently metabolized 
and/or absorbed than the crystalline form, and therefore more effective at improving 
cholesterol levels.  It was surmised that the bioavailability of crystalline oryzanol would 
be enhanced by dissolving the compound in corn oil, although perhaps not extensively 
enough to make its hypolipidemic efficacy comparable to that of the rice bran oil form.  
The secondary objective was to develop methodology for determining the presence of 
oryzanol in serum and liver. 
This study compared amounts of oryzanol in the feces of rats fed one of the 
following forms:  7% oryzanol rice bran oil, crystalline oryzanol, or crystalline oryzanol 
dissolved in corn oil.  Dietary oryzanol recovered from the feces represented that not 
absorbed or metabolized in the gastrointestinal tract.  Various procedures were explored 
to effectively extract oryzanol from serum and liver for quantification by HPLC and 
 4 
GCMS methods.  Serum was analyzed to determine whether or not any oryzanol entered 
the bloodstream without being metabolized.  Livers were analyzed to detect any absorbed 
oryzanol that had not been metabolized.  Total cholesterol levels were assessed using 
both an enzymatic colorimetric method and GCMS. 
Many studies that reported an association between consumption of rice bran oil 
and lower cholesterol levels in rats used high-cholesterol diets.  The rat diets in this study 
were cholesterol- free.  It is likely that a diet containing cholesterol is necessary for the 
hypolipidemic effect of oryzanol to be realized.  Also, if absorption of oryzanol is 
enhanced by cholesterol in the gut, the cholesterol- free diets in this study may have 
resulted in higher fecal oryzanol and lower liver oryzanol than would have occurred with 
cholesterol- fed rats.  Another limitation of this experiment stems from the fact that the 
rats were not fasted prior to sacrifice, preventing meaningful analysis of serum for LDL 
values. 
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CHAPTER 2 
REVIEW OF LITERATURE 
Rice Bran Improves Cholesterol Levels 
Animal Studies 
Various sources of dietary fiber have been shown to lower cholesterol in animal 
models.  Rice bran, in particular, has shown an exemplary capability for improving 
cholesterol status in mice, rats, and hamsters.  This effect appears to be enhanced in diets 
rich in cholesterol.  Hundemer, Nabar, Shriver, and Forman (1991) constructed an 
experiment to compare the cholesterol- lowering effects in mice of rice bran, soybean 
fiber, oat bran, and barley bran when added to a 0.06% cholesterol diet.  Rice bran was 
the most effective bran supplement at lowering liver cholesterol concentrations and 
significantly lowered total plasma cholesterol with respect to the control diet.  In 
addit ion, the HDL cholesterol levels were maintained in mice consuming the rice bran 
diet, resulting in higher HDL to total cholesterol ratios.  
In another study, rats showed significantly lower levels of liver triglycerides and 
liver cholesterol when they were fed a rice bran versus a wheat bran diet (Topping, 
Illman, Roach, Trimble, Kambouris, & Nestel, 1990).  When fish oil was added to test 
diets, rice bran was more effective than wheat bran at preventing the fish oil’s effect of 
decreasing LDL receptor activity and served to enhance the fish oil’s ability to lower 
triglycerides.  The rice bran diet also increased LDL receptor activity in the liver more 
than the wheat bran diet, effectively lowering plasma cholesterol levels.  Again, HDL 
levels were unaffected by the rice bran diets, while a decrease in this “good” cholesterol 
was associated with the wheat bran diets. 
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Hamsters were used to compare the cholesterol- lowering effects of stabilized rice 
bran, parboiled rice bran, rice bran and wheat bran combined, the full- fat and defatted 
versions of each, and oat bran in a 0.5% cholesterol diet (Kahlon et al., 1990).  Liver 
weights were significantly reduced by both full- fat rice bran diets, as were liver 
cholesterol concentrations and total liver cholesterol amounts when compared to the 
control.  The liver cholesterol concentrations in particular were significantly lower in 
animals consuming full- fat stabilized rice bran than all other groups. 
Again, hamsters were used as a model to examine potential cholesterol- lowering 
benefits of varying levels of full- fat rice bran in both 0.3% cholesterol and cholesterol-
free diets (Kahlon et al., 1992).  In animals fed test diets containing dietary cholesterol, 
all groups consuming rice bran diets had significantly lower liver weights than controls 
consuming a diet with cellulose in place of rice bran.  Plasma cholesterol was 
significantly reduced in hamsters consuming the highest level, 43.7%, of rice bran in the 
diet, regardless of dietary cholesterol when compared to the bran- less controls.  
Interestingly, in test groups with cholesterol added to the diet, a significant correlation 
was found between the levels of rice bran in the diet and reductions in plasma cholesterol 
levels. 
Another hamster study, in which dietary cholesterol was only 0.25%, compared 
rice bran diets to diets containing oat bran, whole barley, and various levels of beta-
glucan-enriched barley (Kahlon, Chow, Knuckles, & Chiu, 1993).  No significant 
improvement was seen in either total plasma cholesterol levels or HDL to total 
cholesterol levels.  This appears to contradict other published findings; however, these 
results may be explained by the lower cholesterol content of the test diets used in this 
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experiment.  In contrast, all bran diets showed a significant decrease in total liver 
cholesterol compared to the control. 
A fourth hamster study published by the same primary author was used to 
compare the benefits of adding bran from rice, oats, corn, and wheat to a 0.3% 
cholesterol diet (Kahlon et al., 1998).  In this study, animals fed rice bran had the lowest 
liver weights and liver cholesterol levels.  Liver cholesterol concentrations were 
significantly lower for the rice bran diet than for either the corn or wheat bran diets.  
Although total plasma cholesterol was not significantly lower in any of the treatment 
groups when compared to the control, the levels associated with rice bran were the lowest 
of all bran test diets.  Also, hamsters in the rice bran group had significantly lower VLDL 
levels and the highest HDL to total cholesterol ratios when compared to animals 
consuming all other bran diets.  Finally, the rice bran group showed the lowest 
digestibility rate and the highest lipid excretion rate of all groups. 
Fukushima, Fujii, Yoshimura, Endo, and Nakano (1999) designed an experiment 
to determine if the benefit of rice bran treatment decreased in rats when their cecums 
were removed.  In rats, the cecum is the main site of dietary fiber fermentation which 
produces short chain fatty acids.  The authors theorized that increased levels of short 
chain fatty acids would alter lipid metabolism, perhaps by hindering cholesterol 
absorption due to a change in intestinal fluid viscosity, or by directly inhibiting de novo 
cholesterol synthesis in the liver.  A test diet of rice bran was fed to both cecectomized 
and sham-operated animals.  A third group that did not undergo surgery consumed a 
bran- less diet and served as the control.  Both test diets contained 0.5% cholesterol.  Rice 
bran diets appeared to be responsible for significant reductions in serum total cholesterol, 
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serum triglycerides, and liver cholesterol concentrations.  Although the serum HDL 
levels were also lower in the rice bran groups, HDL to total cholesterol ratios in these 
groups were higher than that of the control group.  The sham-operated group fed rice bran 
showed the lowest liver cholesterol concentrations as well as the lowest total plasma 
cholesterol levels, leading the authors to conclude that rice bran might lower cholesterol 
by increasing short chain fatty acid production in the cecum.  However, Topping et al. 
(1990) found evidence to the contrary.  Although increased short chain fatty acid 
concentration was associated with a rice bran diet relative to a wheat bran diet, no 
correlation between short chain fatty acids and cholesterol was observed.  These 
researchers therefore concluded that the beneficial effect of rice bran with respect to 
cholesterol levels was not due to short chain fatty acid production. 
Human Studies 
Rice bran appears to be effective at improving cholesterol levels in humans, as 
well.  Hegsted et al. (1993) found rice bran to be equivalent to oat bran in lowering 
cholesterol in 11 mildly hypercholesterolemic subjects.  Treatment diets each contained 
300 mg/day of cholesterol and were supplemented with either 100 g/day of stabilized rice 
bran or an equal amount of oat bran.  All subjects consumed both diets during two 3-
week periods that were separated by a 1-week bran- less control diet.  Total cholesterol 
levels were significantly reduced in both bran diets when compared to the control.  
Although HDL levels dropped initially during the bran consumption, the overall effect 
was an improvement in HDL to total cholesterol ratios. 
Changes in plasma lipid levels were studied when 24 men with slightly above 
normal cholesterol levels consumed test diets containing 35 g/day of wheat bran, 60 
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g/day of rice bran, or 95 g/day of oat bran (Kestin, Moss, Clifton, & Nestel, 1990).  The 
varying amounts of the different brans provided a cons tant amount of total dietary fiber 
of 11.8 g/day.  All of the subjects consumed each of the three bran diets in random order 
for 1-week durations.  Only oat bran was effective at reducing plasma cholesterol when 
compared to baseline levels.  However, the highest rise in HDL was associated with the 
rice bran diet, resulting in an improved HDL to total cholesterol ratio.  This ratio was 
significantly higher than that seen in the wheat bran group.  Also, plasma triglycerides 
were lower in the rice bran versus the wheat bran diet, which was again statistically 
significant.  Comparing this study to Hegsted et al. (1993), less dramatic results from the 
rice bran diet may be due to the use of unequal amounts of the various cereal brans. 
In comparing the impact of rice bran on postprandial lipemia with that of oat bran, 
wheat fiber, and wheat germ in males with normal cholesterol, Cara et al. (1992) found 
marginally positive effects.  Test diets were consumed in random order by all subjects 
and were supplemented with 39.4 g of rice bran, 40.0 g of oat bran, 12.5 g of wheat fiber, 
or 40.0 g of wheat germ.  Postprandial serum triglyceride rises were attenuated by all 
cereal additions, including rice bran.  Rice bran also significantly reduced the overall 
chylomicron response to eating, although not as effectively as the other test diets.  Unlike 
the other cereals, rice bran was not associated with significantly lower cholesterol levels 
seven hours after the meal.  The weaker impact of rice bran reported here compared to 
other published findings may be explained due to the following: (1) this study did not 
analyze long-term effects of dietary changes, and (2) subjects had normal levels of 
cholesterol. 
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Oil Fraction of Rice Bran Is Responsible for  
Improving Cholesterol Levels 
 
Animal Studies 
 
Multiple researchers have reported results suggesting that the active component of 
rice bran that is capable of lowering LDL levels while stabilizing or increasing HDL 
levels is in the oil that can be extracted from the bran.  In an effort to promote 
domestically produced edible oil in India, Sharma and Rukmini (1986) explored possible 
health benefits of rice bran oil.  They compared cholesterol and triglyceride levels in rats 
maintained for two months on a diet containing 10% rice bran oil to those of animals fed 
a control diet with an equal amount of groundnut oil.  Half of the animals in each group 
had 0.1% cholesterol and 0.05% cholic acid added in place of a portion of the starch.  In 
cholesterol- fed animals, the rise in serum cholesterol due to the high-cholesterol diet was 
more effectively moderated by rice bran oil than groundnut oil.  Also, HDL levels rose 
significantly in the cholesterol- fed rice bran oil group compared to the cholesterol- fed 
controls.  In addition, serum and liver triglycerides, as well as liver cholesterol, tended to 
be lower in this group.  Similar trends occurred in the rats that did not have added dietary 
cholesterol. 
A later study by Kahlon et al. (1990) found that the ability of rice bran to improve 
cholesterol levels in hamsters diminished when the oil content was removed, leading the 
authors to hypothesize that the oil was the component responsible for the positive effect.  
Edwards and Radcliffe (1994) compared effects of rice bran oil on lipid status to the 
effects of corn oil, which had previously been shown to have a beneficial effect on 
cholesterol levels.  In an evaluation of rats fed cholesterol- free diets containing 10% of 
either rice bran oil or corn oil, no difference was found in serum triglycerides, 
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cholesterol, or phospholipids between the two groups.  Therefore, although the study did 
not utilize a true control group, the researchers concluded that rice bran oil was as 
effective as corn oil in improving cholesterol levels in rats fed cholesterol- free diets.  An 
earlier study comparing the effects of rice bran oil to groundnut oil found superior 
cholesterol- improving effects in rice bran oil.  Significantly lower total cholesterol in 
serum, with a tendency toward higher HDL-cholesterol levels were found in rats 
consuming cholesterol- free, 10% rice bran oil versus groundnut oil diets (Seetharamaiah 
& Chandrasekhara, 1989).  A similar comparison was made in a more recent rat study 
between rice bran oil and high- linoleic acid safflower oil, again using feeds not enriched 
with cholesterol.  Serum cholesterol levels did not differ significantly between the two 
test groups, implying comparable beneficial qualities with respect to cholesterol among 
the two oils (Radcliffe, Imrhan, & Hsueh, 1997). 
In another rat study comparing rice bran and safflower oil, half of the animals 
were randomly assigned to cholesterol- free test diets in which one of these two oils, or a 
varying combination of the two, contributed 10% of the weight (Koba, Liu, Bobik, 
Sugano, & Huang, 2000).  The other half were assigned to similar diets with 0.5% 
cholesterol.  Among the animals not fed dietary cholesterol, total cholesterol levels were 
similar between the rice bran oil and safflower oil groups, but HDL levels were 
significantly higher in the rice bran oil group.  This resulted in a higher HDL:total 
cholesterol ratio for this test group, although the difference was non-significant.  A 7:3 
rice bran oil:safflower oil ratio in the diet appeared optimal with respect to cholesterol 
levels.  The average HDL:total cholesterol ratio was significantly higher for this group 
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than all other groups.  However, the superior effects of both the rice bran oil only group 
and the 7:3 combination group disappeared in the cholesterol- fed animals. 
Human Studies 
In a human study, hyperlipidemic patients who were willing to change their 
dietary habits to reduce risk of heart disease agreed to replace their usual cooking oils 
with rice bran oil (Raghuram et al., 1989).  A control group that continued habitua l use of 
palm or groundnut oils in cooking was used for comparison.  Significant reductions in 
serum cholesterol and triglycerides were seen after 15 days in the experimental group.  
Blood analyses after 30 days revealed even greater variation between the experimental 
and control subjects.  The most responsive patients to the change in dietary oils were 
those with the highest initial cholesterol and triglyceride levels. 
A later study compared the hypolipidemic impact of rice bran oil with canola, 
corn, and olive oils, which are more commonly used in Western diets, again using human 
subjects with moderately elevated blood cholesterol levels (Lichtenstein et al., 1994).  All 
diets contained 80 mg of cholesterol with one of the four oils constituting two-thirds of 
the fat in the different diets and were all consumed for one month by each subject in a 
random order.  Total and LDL cholesterol levels were similar during the rice bran, canola 
and corn oil-enriched diet consumption periods.  These oils resulted in total and LDL 
cholesterol levels that were significantly lower than when subjects were maintained on 
the diet containing olive oil.  No significant variation in HDL levels among the four 
groups meant that inferior cholesterol ratios were associated with the olive oil diet in 
relation to the others.  All diets showed similar results with respect to plasma 
triglycerides.  The outcome of this study suggests that rice bran oil can be considered as 
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beneficial as the more commonly consumed canola and corn oils with respect to heart 
disease risk factors in hyperlipidemic subjects. 
Unsaponifiable Fraction of Rice Bran Oil Is 
Capable of Hypolipidemic Action 
 
Animal Studies 
 
Early research by Sharma and Rukmini (1987) explored the possibility that the 
unsaponifiable portion of rice bran oil alone was responsible for hypocholesterolemic 
effects.  A control group of rats was maintained for eight weeks on a 1% cholesterol diet 
with 10% groundnut oil and was compared to three experimental groups.  In these 
groups, either 0.2% or 0.4% unsaponifiable matter of rice bran oil was added or rice bran 
oil replaced groundnut oil.  Although the 0.2% unsaponifiable addition was ineffective at 
significantly altering cholesterol levels compared to the control group, both the rice bran 
oil substitution and the 0.4% addition of unsaponifiables significantly lowered liver 
triglycerides, liver cholesterol, and total serum cholesterol while maintaining HDL levels.  
Cholesterol levels were statistically indistinguishable between the diet containing 
groundnut oil plus 0.4% unsaponifiables from rice bran oil and the diet in which the 
groundnut oil was replaced with rice bran oil, showing that the active component is likely 
contained in the unsaponifiable fraction. 
Nagao, Sato, Takenaka, Ando, Iwamoto, and Imaizumi (2001) recently reported 
similar benefits of unsaponifiables prepared from rice bran oil in a strain of exogenously 
hypercholesterolemic rats.  Animals were maintained for two weeks on a 0.5% 
cholesterol diet with a 10% fat content from: (1) rice bran oil, (2) a mixture of palm and 
safflower oils with a similar fatty acid content to that of rice bran oil, or (3) the oil 
mixture described in (2) plus 0.25% of unsaponifiable content prepared from rice bran 
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oil.  Serum and liver total cholesterol concentrations were significantly lower and HDL 
levels significantly higher in both groups of rats consuming the unsaponifiables (within 
rice bran oil or added to the simulated rice bran oil) versus rats assigned to the simulated 
rice bran oil without added unsaponifiables.  Higher fecal excretion of cholesterol was 
noted in the two unsaponifiable groups as well, although bile acid and coprostanol 
excretion was similar in all three groups.  Analysis of liver mRNA’s revealed no 
differences in prevalence of HMG-CoA reductase, LDL receptors, or cholesterol 7a-
hydroxylase among the three experimental groups.  This information led the authors to 
conclude that the unsaponifiable fraction of rice bran oil acts to lower cholesterol by 
interrupting cholesterol absorption in the gut, and not by altering hepatic cholesterol 
metabolism.  
In a recent primate study, monkeys were fed in random order a control diet 
representative of the typical American diet and three experimental diets in which 20% of 
the energy content was comprised of either rice bran oil, canola oil, or corn oil (Wilson et 
al., 2000).  Based on the comparative fatty acid contents of the three oils, both canola and 
corn oil diets were expected to outperform the diet containing rice bran oil.  However, 
HDL levels were maintained on the rice bran oil diet and fell during consumption of the 
other two.  No significant variation among the diets was noted with respect to total 
cholesterol levels.  Given the higher saturated fat content and lower unsaturated fat 
content of the rice bran oil, these results suggest the unsaponifiable fraction is critical for 
this oil’s ability to decrease risk of cardiovascular disease. 
Human Studies 
 Lichtenstein et al. (1994), whose research was referred to previously, found 
hypolipidemic effects of rice bran oil to be comparable to that of canola, corn, and olive 
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oils in human subjects with moderately elevated cholesterol levels.  Since results from the 
rice bran oil-enriched diet exceeded predictions using calculations based on fatty acid 
content, the authors surmised that a fraction of the oil other than the fatty acid portion, 
likely the unsaponifiables, must be acting to lower total cholesterol. 
 An experiment designed to assess the impact of plant sterols present in the 
unsaponifiable fraction from rice bran oil, used healthy volunteers with normal 
cholesterol levels (Vissers, Zock, Meijer, & Katan, 2000).  The subjects were instructed 
to continue usual dietary and physical activity habits while supplementing their diets with 
a control margarine containing only trace amounts of plant sterols or one enriched with 
2.1 g/day of the sterols from rice bran oil for three weeks each.  The enriched margarine 
significantly lowered total and LDL cholesterol versus the control.  HDL levels were 
unaffected by consumption of the enriched margarine. 
Oryzanol in Unsaponifiable Fraction of Rice Bran Oil Is an 
Active Hypolipidemic Ingredient 
 
Animal Studies 
 
It has been hypothesized that oryzanol is the primary active ingredient in rice bran 
oil that is responsible for its ability to improve cho lesterol levels.  Seetharamaiah and 
Chandrasekhara (1989) attempted to answer the question of whether or not oryzanol was 
the sole ingredient in rice bran oil inducing this positive effect on cardiovascular health 
status.  They examined the impact of the addition of 0.5% oryzanol to an experimental 
diet enriched with 1% cholesterol and 10% refined rice bran oil that contained only trace 
amounts of oryzanol.  Liver weights of rats fed oryzanol were lower than those 
maintained on diets consisting of refined rice bran oil with no added oryzanol.  In 
addition, the oryzanol-supplemented diet was associated with lower total cholesterol
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levels.  However, since improved cholesterol status was also observed in rats fed the diet 
with refined rice bran oil when compared to those maintained on a control diet containing 
10% groundnut oil, the authors concluded that oryzanol, although critical, could not be 
the only active component. 
Assuming oryzanol to be an important element in improving cholesterol levels, 
the optimal dosage and length of treatment time necessary to realize benefits was studied 
(Seetharamaiah & Chandrasekhara, 1988).  Oryzanol was extracted from rice bran as 
detailed by Seetharamaiah and Prabhakar (1986), and was added in a crystalline form to 
test diets in varying amounts.  Rats were randomly assigned to diets that were enriched 
with 1% cholesterol and 0.15% bile salts, and either devoid of oryzanol or oryzanol-
enriched at levels of 0.2, 0.5, 1.0 and 2.0%.  A control group was fed a diet free from 
both cholesterol and oryzanol.  Liver weights of cholesterol- fed rats were significantly 
lower when oryzanol of any percentage was consumed.  Significant variations in blood 
cholesterol levels were present by week five, at which time oryzanol- fed animals had 
lower levels compared to all other cholesterol- fed rats.  Oryzanol also appeared to 
prevent HDL levels from dropping due to dietary cholesterol.  A significant decrease in 
plasma triglyceride levels was seen in the 0.5% oryzanol group.  Due to this apparent 
advantage, and the fact that liver cholesterol, triglycerides, and phospholipids in this 
group were significantly lower than in rats fed diets not enriched with oryzanol, the 
authors concluded that 0.5% oryzanol was an optimal dosage.   
Research in this same laboratory was conducted to compare the cholesterol-
lowering ability of oryzanol to that of two known hypolipidemic compounds, curcumin 
(yellow pigment in turmeric) and ferulic acid (Seetharamaiah & Chandrasekhara, 1993).  
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Rats fed a high cholesterol diet had similar HDL levels, but significantly higher serum 
cholesterol levels than animals maintained on a similar diet supplemented with any of the 
three compounds being tested.  The most preferred HDL:LDL ratio was seen in the 
oryzanol- fed group.  Both oryzanol and curcumin were effective at lowering total liver 
cholesterol, as well as esterified cholesterol and triglycerides.  The authors reported 
oryzanol as a superior hypolipidemic agent to curcumin and ferulic acid. 
Rong, Ausman, and Nicolosi (1997) published findings touting the ability of 
oryzanol to reduce cholesterol absorption in hamsters.  Animals were sustained for 7 
weeks on a hypercholesterolemic diet of 5% coconut oil and 0.1% cholesterol to which 
either no or 1% oryzanol had been added.  Both oryzanol and cholesterol were dissolved 
in the coconut oil prior to being added to the diet.  The oryzanol supplemented diet was 
associated with a significant decrease in total and non-HDL cholesterol levels in plasma.  
Compared to the control group, the oryzanol- fed animals experienced a 25% reduction in 
percent cholesterol absorption.  In contrast, liver and intestinal HMG-CoA reductase 
activities were similar between the groups suggesting no differences in endogenous 
cholesterol synthesis. 
A second experiment from which results were published in the same paper was a 
modification of the first.  The oryzanol level in the experimental diet was reduced from 
1.0% to 0.5% and the length of the study was increased to 10 weeks.  Again, hamsters 
ingesting oryzano l showed an improved cholesterol status.  Compared to the controls, this 
group had reduced plasma total cholesterol, reduced triglycerides, and more optimal 
HDL:non-HDL ratios.  The authors concluded that oryzanol was a critical component of 
rice bran oil’s hypolipidemic capacity and that its ability to reduce dietary cholesterol 
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absorption was at least partially responsible for the improved cholesterol status seen in 
oryzanol- fed hamsters. 
Human Studies 
Sixty-seven patients with elevated cholesterol levels volunteered to take 300 
mg/day of gamma-oryzanol so that its effect on cholesterol in humans could be examined 
(Yoshino et al., 1989).  Although there was no control group, the patients were stratified 
into three groups according to the World Health Organization hyperlipidemia 
classification and encouraged not to change dietary or lifestyle habits for the 3-month 
duration of the study.  All groups experienced a decline in total cholesterol levels, and to 
a significant degree in type IIb (high cholesterol and high triglycerides) and IIa (high 
cholesterol only) patients.  At the conclusion of the experiment, mean values for total 
triglyceride levels were significantly lower and the type IIb subjects showed a significant 
increase in HDL levels.  It should be noted that, although significant, these were small 
changes in cholesterol status.  Importantly, however, no adverse effects of oryzano l 
supplementation were observed. 
Absorption of Oryzanol 
To my knowledge, only one publication to date attempts to quantify the 
absorption of oryzanol.  Fujiwara, Sakurai, Sugimoto, and Awata (1983) investigated the 
absorption and metabolism of gamma-oryzanol in rats by (1) administering an oral dose 
of a triolein solution of radioactively labeled gamma-oryzanol at the C-3 position of 
ferulic acid, and (2) injecting the radioactively labeled compound into the mid-ileal 
lumen of the small intestine.  In the oral dose portion of the experiment, radioactive 
urinary and fecal excretion lasted for 72 hours.  The fecal radioactive excretion 
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represented 84.5% of the total dose.  While 9.8% of the radioactivity was recovered in the 
urine, the fraction of urine expected to have contained oryzanol did not show any 
radiation, leading the authors to believe that oryzanol absorbed in the intestine was 
completely metabolized in the body.  Radioactivity was also detected in the blood, 
reaching the highest level of radioactivity four hours after oral administration.  When 
radioactive- labeled gamma-oryzanol was injected into the lumen, the majority of it 
remained in the luminal fluid, suggesting that oryzanol is poorly absorbed in the gut. 
Measurement of Absorption of Oryzanol in Liver 
To my knowledge, no studies have measured the absorption of oryzanol in liver 
without using radioactive tracers.  However, a plethora of research exists in which 
cholesterol in this organ is quantified.  Oryzanol from rice bran oil is a mixture of at least 
ten ferulate esters of triterpene alchohol (Xu & Godber, 1999).  The chemical structures 
of the triterpene alcoho ls are similar to that of cholesterol (Figure 1, Figure 2).  
Therefore, it is logical to attempt to measure oryzanol using an accepted method for 
measuring cholesterol. 
 
O
O
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FIGURE 1  Cycloartenyl ferulate, a common form of oryzanol. 
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FIGURE 2  Cholesterol. 
 
A review of the literature disclosed that scientists frequently chose the extraction 
method of Folch, Lees, and Stanley (1957) to extract lipids from tissues (Koba et al., 
2000; Fukushima et al., 1999; Hundemer et al., 1991).  Others used modified versions of 
this technique (Lee, Akoh, Flatt, & Lee, 2000; Wilson et al., 2000).  After extracting 
lipids from liver or adipose tissue, various methods such as enzymatic kits (Kahlon et al., 
1992, 1993, 1998; Hundemer et al. ; Wilson et al.), gas-liquid chromatography 
(Fukushima et al., 1999) and high performance liquid chromatography (HPLC) (Koba et 
al.; Lee et al.) were used to quantify the cholesterol.  Xu and Godber (1999) have 
demonstrated that oryzanol in rice bran oil can be accurately quantified using an HPLC 
method. 
Summary 
Varying and sometimes conflicting results have been reported regarding the 
effects of rice bran, rice bran oil, the unsaponifiable content of rice bran oil, and oryzanol 
on serum and liver cholesterol.  Many variables were at work including the species used, 
the duration of the studies, the specifications for the diets, and the analytical methods 
utilized.  Nevertheless, the body of research suggests that rice bran or a component of 
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rice bran, such as oryzanol, is likely capable of lowering risk of heart disease by 
improving cholesterol levels. 
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CHAPTER 3 
METHODS 
Animals and Diets 
 Sprague Dawley, nine month old, retired breeder rats were purchased from Harlan 
Sprague Dawley, Inc. (Indianapolis, IN) to serve as the animal models.  Upon arrival, 
laboratory animals were individually housed in suspended wire-mesh-bottomed, stainless 
steel cages in a temperature controlled room with a 12-hour light/dark cycle.  Animals 
were allowed free access to feed and water during the entire study.  A total of 47 rats 
were blocked by weight and then randomly assigned to a treatment group.  Twenty rats 
were used as controls and the remaining 27 were equally divided among three 
experimental diet groups.  All rats assigned to experimental diets and half of the rats 
serving as controls were ovariectomized two weeks into the study, while the remaining 
control animals underwent a sham surgery. 
All diets (Table 1) were a modification of the AIN-93M rodent diet formulated by 
Reeves, Nielsen, and Fahey (1993) for nutritional maintenance of adult rats.  
Experimental diets were a replication of the control (C) diet with the exception of the 
substitution of high-oryzanol rice bran oil for corn oil in the rice bran oil (RO) diet, and 
the addition of 2.8 g/kg oryzanol in the crystalline oryzanol (CO) and dissolved oryzanol 
(DO) die ts.  The 2.8 g/kg of supplemental oryzanol was calculated based on the 7% 
oryzanol content of the high-oryzanol rice bran oil to allow for an equal amount of 
oryzanol in all three test diets.  Rice bran oil used in the RO diet was donated by 
Riceland, Inc. (Stuttgart, AR).  Crystalline oryzanol, purchased from Samlong Chemical 
Co., LTD. (Changxin, Jiangsu, China), and corn oil stripped of tocopherols, purchased 
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from Dyets, Inc. (Bethlehem, PA), were used in the CO and DO diets.  Crystalline 
oryzanol and corn oil were simply added as separate ingredients in the CO feed mixture.  
For the DO group, crystalline oryzanol was completely dissolved in the corn oil portion 
by stirring constantly with a stirbar for approximately one hour on a slightly warmed hot 
plate before adding the solution to the diet mix.  The diets were stored in air-tight 
containers at -20 °C. 
TABLE 1 
 
Diets in grams per kilogram. 
 
Ingredients C RO CO DO 
Casein 150 150 150 150 
Sucrose 100 100 100 100 
Cornstarch 455.7 455.7 455.7 455.7 
Dextrinized cornstarch 155 155 155 155 
Corn oil, stripped 40 0 40 40 
Rice bran oil 0 40 0 0 
Cellulose 50 50 50 50 
Mineral Mix 
AIN-93M 
35 35 35 35 
Vitamin Mix 
AIN-93M 
10 10 10  10 
Choline bitartrate 2.5 2.5 2.5 2.5 
L-cystine 1.8 1.8 1.8 1.8 
Oryzanol 0 0* 2.8 2.8** 
*Oryzanol (2.8 g) was contained in the high-oryzanol rice bran oil; no additional amount 
was added. 
**Dissolved in the stripped corn oil. 
Diet samples were analyzed using a reverse-phase high-performance liquid 
chromatographic (HPLC) method in order to verify the oryzanol content of each test diet.  
To prepare each sample for analysis, a 0.25 g portion was weighed in a 10-mL glass test 
tube.  Five mL of hexane was then added and the contents were vortexed for 15 seconds.  
This was followed by incubation in a 60 °C water bath for 30 minutes.  The test tube was 
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removed and vortexed for 15 seconds, twice, at equal intervals during the water bath and 
finally upon removal.  The sample was then centrifuged using a Beckman model J-6B 
centrifuge (Palo Alto, CA) at 4,000 xg for 10 minutes and a portion of the upper layer of 
hexane solution was siphoned off and transferred into a vial for HPLC analysis. 
The HPLC system (Waters, Milford, MA) and method of analysis was as 
described by Xu and Godber (1999) in their separation of gamma-oryzanol components.  
Fifty µL of prepared extract was injected using a Waters 715 Ultra Wisp autosampler.  A 
mobile phase of methanol:acetonitrile:dichloromethane:acetic acid (50:44:3:3) was used 
at a flow rate of 1.4 mL/min (Waters 510 pump) with a C18 reverse phase column from 
Supelco (4.6 mm x 25 cm, Bellefonte, PA).  The Waters 486 tunable absorbance detector 
was set at a wavelength of 330 nm.  Analysis was performed in triplicate for each of the 
three oryzanol-containing diets and the values within each group were averaged.  A 
formula based on a standard curve for oryzanol was used to convert peak areas to mg/g 
units (Appendix A). 
Data Collection 
Food was replenished on Monday, Wednesday, and Friday of each week and food 
intake was calculated as weight of food offered less that not eaten or spilled.  Body 
weights were recorded once per week and notes were made regarding any health 
problems.  At weeks 6 and 10, each animal was placed in an individual metabolism cage 
for 24 hours according to a random schedule to collect feces.  Samples were collected in 
plastic containers and frozen until analyzed. 
 Daily oryzanol intake for each rat was calculated as the product of the percent 
oryzanol in each diet as determined by the HPLC analysis, and the average daily amount 
 25 
of food consumed during and one to four days prior to its 24-hour stay in the metabolism 
cage.  The number of days averaged to obtain the daily intake value varied due to the 
Monday, Wednesday, Friday food intake record and the random metabolism cage 
schedule.  The decision to use averaged data over these time periods was based primarily 
on findings from two recent rat stud ies.  Dvir et al. (2000) reported 15.06 hours were 
required for the first detection of excreted intake from a 2% cellulose diet.  In a separate 
study, 19.5 to 24.7 hours were required for 80% of intake from a 5% fiber diet to be 
excreted (Ferguson & Harris, 1998).  The diets used in the current study contained 5% 
fiber from cellulose.  Additionally, Fujiwara et al. (1983) noted that radioactive fecal 
excretion ceased within 72 hours of an oral dose of radioactively labeled gamma-
oryzanol administered to rats. 
 Beginning on Monday of week 12, approximately 10 rats were sacrificed each 
morning in random order.  Animals were anesthetized with isoflurane and terminated via 
cardiac puncture and cervical dislocation.  Whole blood drawn from cardiac puncture in 
the morning was collected in a glass vacutainer, placed on ice and allowed to clot.  
Samples were centrifuged each afternoon at 1,000 xg for 10 minutes at room temperature 
using a Dynac™ centrifuge (Clay Adams, Parsippany, NJ).  The resulting serum was 
placed in eppendorf tubes and frozen at -20 °C.  Livers were excised, rinsed, blotted, 
weighed, divided into three aliquots, wrapped in aluminum foil, and placed immediately 
in liquid nitrogen.  Livers were transferred later the same day to a freezer maintained at  
-20 °C for storage. 
Fecal Analysis 
 Feces were analyzed for oryzanol content by HPLC so that the percentage of 
dietary oryzanol that was neither absorbed nor metabolized could be compared among the 
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three diet groups.  In preparation for analysis, frozen fecal specimens were allowed to 
thaw at room temperature.  The specimens were then transferred to individual glass jars 
and dried in a VWR 1410 vacuum oven (West Chester, PA) at 60 °C and –15 inHg of 
pressure.  Samples were weighed periodically during the drying process to verify that 
moisture had been eliminated.  Once dehydrated, each sample was ground with a mortar 
and pestle, returned to the glass container, capped, and placed in a Dry-Keeper desiccator 
cabinet purchased from Bel-Art Products (Pequannock, NJ) for storage.  A 0.25 g portion 
of each of the dried fecal samples was analyzed using HPLC by an identical method as 
detailed for the diet analysis above.  Again, peak areas were converted to mg/g units 
according to a formula based on a standard curve for oryzanol (Appendix A).  The daily 
fecal excretion of oryzanol was extrapolated from the amount of oryzanol detected in 
each 0.25 g fecal sample.  Daily fecal excretion of oryzanol was divided by daily 
oryzanol intake to provide the percentage of dietary oryzanol recovered in the feces. 
Serum Analysis 
Cholesterol Quantification Using Enzymatic Colorimetric Assay 
 To examine the effect of the various diets on cholesterol levels, serum samples 
from all five groups were analyzed for total cholesterol using an enzymatic colorimetric 
method (Infinity™ cholesterol reagent, procedure no. 401, Sigma Diagnostics, Inc., St. 
Louis, MO).  Serum was allowed to thaw at room temperature prior to lipid analysis.  Ten 
µL of serum sample was added to 1.0 mL of reagent in a glass test tube.  The contents  
were vortexed and allowed to incubate in a 37 °C water bath for five minutes before a 
portion was transferred to a cuvette.  Colorimetric readings were done using a Hitachi U-
2000 UV/Vis spectrophotometer (Weston, MA) set at 500 nm.  Assays were performed in
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duplicate.  When the reproducibility of assay values for a particular sample was at least 
90%, the two values were averaged.  Otherwise, a third assay was performed and an 
average of all three was used.  To reduce variation caused by possible hemolysis of the 
sample, the absorption value was reduced by the colorimetric reading obtained from 
analyzing 10 µL of serum added to 1.0 mL of water.  The total cholesterol value was then 
calculated by dividing the adjusted absorption value of the prepared serum sample by the 
absorption value of the calibrator, and multiplying the result by the concentration of the 
calibrator, 200 mg/dL (Appendix A). 
Oryzanol Detection Using GCMS 
 Unexpected results of higher cholesterol levels in oryzanol- fed rats compared to 
the controls led to the question of whether or not the assay was measuring phytosterols as 
well as cholesterol.  Therefore, a serum sample from the RO group was prepared for 
analysis by gas chromatography and mass spectrophotometry (GCMS) to determine the 
presence of oryzanol.  The serum sample was allowed to thaw at room temperature and 
0.5 mL was measured into an 8-mL glass vial.  An extraction was done by adding 1.0 mL 
of hexane, vortexing for 15 seconds, centrifuging for 10 minutes at approximately 500 
xg, and transferring the supernatant to a clean 10-mL test tube.  The hexane extraction 
was repeated twice and the resulting extract was divided between two test tubes.  A 
Zymark TurboVap LV evaporator (Hopkinton, MA) with a nitrogen flow at 10 psi and 45 
°C for 20 minutes was used to evaporate the solvent.  One test tube was stored for 
possible future analysis, while contents in the other test tube were derivatized by adding 
0.1 mL of pyridine and 0.1 mL of N,O-bis(trimethylsilyl) acetamide (BSA) + 
trimethylchlorosilane (TMCS) from Supelco (Bellefonte, PA).  This was vortexed and 
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placed in a 30 °C water bath for 30 minutes.  GCMS was performed as described by Xu 
and Godber (1999).  One µL of derivatized sample was injected into a Saturn 2000 
GCMS (Varian, Walnut, Creek, CA) with an injection port temperature of 300 °C.  The 
initial oven temperature was 100 °C and was increased 3 °C per minute to a maximum of 
280 °C.  Helium was used as the carrier gas at a flow rate of 1.0 mL/min. 
 The resulting chromatograph of the RO sample revealed small peaks with greater 
retention times than the cholesterol peak, suggesting the  possible presence of 
phytosterols.  To determine whether these peaks included oryzanol, the procedure was 
repeated with a sample from the C group for comparison.  When similar peaks resulted 
from GCMS analysis of the C serum, the possibility of the peaks being representative of 
oryzanol was eliminated. 
Cholesterol Quantification Using GCMS 
Hexane Extraction.  To validate the cholesterol values from the enzymatic 
colorimetric assay, the serum sample set was reanalyzed for total cholesterol via GCMS.  
An 8.7 ppm stock solution of a-cholestane dissolved in hexane served as a standard.  
After allowing serum samples to thaw at room temperature, 0.25 mL of serum and 1.0 
mL of the internal standard stock solution was measured into a 7-mL glass vial.  (Only 
0.25 mL of stock solution was added to the first five samples.  Following analysis of 
these samples, the amount of stock solution was adjusted from 0.25 to 1.0 mL to obtain 
internal standard and cholesterol peak areas of similar size).  Next, one mL of hexane was 
added.  The contents were vortexed, shaken vigorously, and then centrifuged at 1,000 xg 
for 10 minutes.  The supernatant was transferred to a clean test tube.  This extraction 
process was performed in triplicate, each time transferring the supernatant to the same 
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test tube.  The cumulative solvent was evaporated using a CentriVap Console vacuum 
centrifuge (Labconco, Kansas City, MO) at 45 °C for 20 minutes.  The samples were then 
derivatized by adding 0.1 mL pyridine and 0.1 mL BSA + TMCS, capping, vortexing, 
and incubating in a 30 °C water bath for 30 minutes.  One µL of sample was injected into 
the GCMS for quantification of cholesterol under the same conditions as outlined above. 
 Chloroform:Methanol Extraction.  Results from GCMS analysis of serum 
following extraction with hexane varied greatly from sample to sample.  Due to these 
unintelligible values, the method was abandoned prior to completing analysis of the 
entire sample set.  In a second attempt, the methodology was adjusted to extract lipids 
according to Folch, Lees, and Sloane Stanley (1956).  A 2:1 solution of 
chloroform:methanol was used as the reagent.  The internal standard a-cholestane (0.7 
mg) was added directly to the reagent (250 mL), creating a 2.8 ppm concentration.  Per 
Folch et al., a rinsing solution was created by mixing an 8:4:3 ratio of chloroform: 
methanol:water, allowing layers to form, and retaining the upper phase.  The amount of 
rat serum remaining from the study constrained the following analysis to three samples 
per diet group.  One-half mL of serum and 7.0 mL of chloroform:methanol reagent was 
added to a 15-mL test tube.  The contents were vortexed for 30 seconds and then filtered 
by pouring into a small glass funnel lined with Whatman 7.0 cm No.1 qualitative filter 
paper (Springfield Mill, Maidstone, Kent., England).  An additional 3.0 mL of reagent 
was used to rinse the filter paper.  The filtered solution was collected into a clean 15-mL 
test tube and 2.0 mL of distilled water was added.  Contents were vortexed for 30 seconds 
and centrifuged at 2,000 xg for five minutes in a Hermle Z383K centrifuge from Labnet 
International, Inc. (Woodbridge, NJ).  The supernatant was removed using a Pasteur 
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pipette and discarded.  Twice, approximately 1.5 mL of the rinsing solution was used to 
rinse the tube, and again the supernatant was discarded.  Next, 2.0 mL of methanol was 
added, the contents were vortexed 30 seconds, and the solvents were completely 
evaporated in the CentriVap Console at 45 °C for 2 ½ hours.  Derivitization followed 
using 0.1 mL each of pyridine and BSA + TMCS as described previously.  The 
dervatized contents were diluted with 1.8 mL of hexane prior to being injected into the 
GCMS instrument.  The settings for the GCMS were identical to those detailed 
previously. 
 Standard Curve.  A standard curve was produced in order to translate GCMS 
peak areas obtained for cholesterol into actual serum cho lesterol concentrations.  Fifty 
mL of hexane was added to 2.0 mg of cholesterol standard.  One mL of this solution was 
added to each of three 15-mL test tubes.  The solvent was evaporated in the CentriVap 
Console set at 45 °C for 20 minutes.  Next, 10.0 mL of the 2.8 ppm solution of a-
cholestane in chloroform:methanol reagent was added to each test tube.  Again, the 
solvent was evaporated using the CentriVap Console set at 45 °C for 2 ½ hours.  To 
create varying degrees of dilution, the following amounts of hexane were added to the 
three test tubes containing the cholesterol and a-cholestane standards:  1.3, 1.8, and 2.3 
mL.  One µL from each dilution was injected for GCMS analysis.  Again, GCMS 
specifications remained the same as mentioned earlier.  (See Appendix A for resulting 
formula). 
Liver Analysis 
Developing Methodology for Oryzanol Quantification 
 Detection of oryzanol in the liver would suggest that at least some oryzanol is 
absorbed intact.  Several procedures were tested to formulate an acceptable methodology 
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for preparing liver samples for quantification of oryzanol content using HPLC or GCMS 
analysis.  A 0.25 g portion of liver from a rat not included in the feeding study was 
weighed and placed in a glass tube with a conical shaped bottom.  Two mL of hexane 
were added and the contents were homogenized using a Duall® PTFE pestle 
(Kimble/Kontes, Vineland, NJ) suitable for soft tissues.  The pestle was driven by a 
Black & Decker ¼ inch, 120 volt drill (Townsend, MD) with electrical power supply 
regulated at 60 volts by a variable transformer.  Aluminum foil was wrapped around the 
top of the conical tube during homogenizing to limit evaporation of the solvent.  
Although portions of blended liver adhered to the pestle and tube, it was apparent that the 
tube could easily handle a larger liver sample.  Therefore, in a second attempt, the liver 
size was increased to 0.5 g and hexane was added incrementally (0.5 mL and 1.0 mL) 
during homogenization and a final 1.0 mL was used to flush the pestle and tube.  The 
benefit of flushing was questionable as the majority of the liver tissue appeared to remain 
on the inside of the conical tube.  The products of both of these methods were discarded. 
Two samples of liver excised from a rat not included in the feeding regimen for 
this project, along with two samples of liver from a rat in the RO group, were prepared 
for analysis next.  A 0.5 g portion of each was weighed and placed in a conical tube.  The 
duplicate sample from the rat not in the study was spiked with 0.005 g of crystalline 
oryzanol.  Again, hexane was added incrementally in amounts of 0.5 mL and 1.0 mL with 
homogenization after each addition.  Finally, 0.5 mL of hexane was used to flush the 
pestle.  However, flushing did not appear to be advantageous and was abandoned in 
future procedures.  Homogenized mixtures were transferred to clean test tubes and each 
was vortexed for 15 seconds and centrifuged for 10 minutes at 4,000 xg.  Prior to
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centrifuging, the duplicate sample from the RO rat was incubated in a 60 °C water bath 
for 30 minutes, and vortexed twice at 10 minute intervals during incubation and upon 
removal.  The supernatants of each of the four samples were transferred to HPLC vials.  
The same method used to determine oryzanol content in the feces and diet via HPLC 
analysis was followed. 
Curves produced by the chromatograph for the two samples representing the RO 
group did not differ substantially, suggesting that the incubation period was superfluous 
(Appendix B).  Although the areas beneath the curves of these RO samples were greater 
than that of the first sample from the rat not fed oryzanol, all three curves were similar in 
shape and did not resemble the curve of the duplicate sample to which crystalline 
oryzanol had been added.  Since the peak did not represent oryzano l, the compound being 
detected was unknown. 
HPLC Analysis 
The method was adjusted slightly a fourth and final time and one liver from each 
of the five experimental groups was analyzed.  Additionally, a duplicate sample of liver 
from group C was spiked with 0.01 g of cholesterol in an attempt to identify the visible 
peak.  Again, approximately 0.5 g of liver was weighed and placed in a conical glass 
tube.  One mL of hexane was added and the contents were homogenized for 60 seconds.  
Another 1.0 mL of hexane was added and the contents were homogenized an additional 
30 seconds.  The homogenate was poured into a clean test tube and centrifuged at 4,000 
xg for 10 minutes.  The supernatant was transferred into a vial and HPLC analysis as 
detailed previously was performed.  Peaks resulting from HPLC analysis of liver did not 
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appear to be representative of oryzanol or cholesterol.  Therefore, GCMS technology was 
utilized next to identify the compound being detected. 
GCMS Analysis 
During a repeated HPLC analysis of a liver extract from the RO group, the most 
prominent peak was collected into a clean test tube.  Solvents were evaporated under 
nitrogen flow at 45 °C for 30 minutes at a pressure of 10 psi.  The sample was derivatized 
by adding 0.1 mL of hexane, 0.2 mL of BCl3-methanol, and 0.1 mL of 2,2-
dimethoxypropane.  The mixture was incubated for 10 minutes at 60 °C.  Upon removal, 
0.5 mL of hexane and 0.1 mL of water were added and the tube was shaken.  Layers were 
allowed to form and the upper organic layer was transferred using a Pasteur pipette into a 
clean vial containing a small amount of anhydrous sodium sulfate.  Again, the tube was 
shaken, contents were allowed to settle, and the upper layer was transferred into a clean 
vial.  GCMS analysis was performed using specifications as detailed above for serum 
samples.  A search of probable compounds associated with the resulting GCMS peaks 
revealed that the collected sample most likely consisted primarily of C:16 fatty acids.  
Oil Analysis 
 HPLC analysis of the tocopherol-stripped corn oil used in the CO and DO diets 
was conducted to verify that any phytosterols present in the oil would not be measured as 
oryzanol.  The high-oryzanol rice bran oil used in the RO diet was analyzed for 
comparison.  Approximately 0.5 g each of oil were weighed into glass test tubes.  An 
extraction was carried out by adding 2.0 mL of hexane, vortexing for 15 seconds, and 
centrifuging for 10 minutes at 4,000 xg.  The supernatant was transferred into an HPLC 
vial for analysis as previously described.  
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Statistical Analysis 
 The SAS statistical software package version 8.2 (SAS Institute, Cary, NC, USA) 
was used to analyze the data from this study.  Analysis of variance (ANOVA) was 
performed using PROC MIXED to compare the percentage of dietary oryzanol recovered 
in the feces among the three experimental groups fed oryzanol.  Comparisons were also 
made between the two fecal collection periods, as well as among diet group and 
collection period combinations.  Tukey’s test was used to determine specific differences 
among the data.  Total cholesterol levels of all five test groups were also compared using 
ANOVA obtained via PROC GLM.  Results were considered significant when p £ 0.05. 
Human Pilot Study 
 A pilot study was designed to determine if any oryzanol from the high-oryzanol 
rice bran oil might be absorbed in the human gut and present in a sufficient amount in the 
blood to be detected.  Also, using human serum to investigate the possible presence of 
oryzanol allowed for conservation of rat serum needed for cholesterol analysis.  The 
average daily intake of rice bran oil for the RO group was used to calculate a comparable 
daily intake for a 70 kg person based on body weight.  This resulted in an amount that 
was unfeasible to consume.  Therefore, a second calculation was done based on the 
percentage of calories in the rat diet attributable to the rice bran oil (Appendix C).  It was 
estimated that the RO test diet contained 9.6% of calories as rice bran oil.  For a 2,000 
kcal diet, 21.33 g of rice bran oil would provide 9.6% of the calories.  A muffin recipe 
(Appendix D) was modified to contain double this amount in a yield of six muffins, so 
that three muffins per day could be consumed by a human volunteer during a 48-hour 
period. 
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 A non-fasting blood sample was drawn at 1:00PM by the Student Health Center at 
Louisiana State University.  The lab provided serum prepared by allowing the whole 
blood to clot and then centrifuging and transferring to a clean glass vacutainer.  The 
serum was divided into three eppendorf tubes and stored at -20 °C.  The human volunteer 
consumed six muffins according to the following schedule: 
Day 1 
1:30PM – muffin 1 
7:30PM – muffin 2 
 
Day 2 
9:00AM – muffin 3 
2:00PM – muffin 4 
8:00PM – muffin 5 
 
Day 3 
8:00AM – muffin 6 
 
A second non-fasting blood sample was drawn at 1:00PM on day three by the 
LSU Student Health Center and the resulting serum was provided.  The same protocol 
was followed as for the first blood drawn. 
HPLC Analysis of Serum for Oryzanol Detection 
The before and after serum samples were analyzed for oryzanol content via 
HPLC.  A 0.3 g portion of each sample was weighed in a test tube in duplicate.  Two mL 
of hexane was added to each test tube and the contents were vortexed for 15 seconds.  
Samples were then centrifuged at 4,000 xg for 10 minutes and the supernatant was 
transferred to an HPLC vial.  The HPLC analysis was performed as described previously 
for rat serum.  Results from this procedure did not reveal any oryzanol, and graphs from 
the HPLC analysis of the before and after serum were indistinguishable.  To produce a 
more concentrated extract, 1.0 g of serum was mixed with 2.0 mL of hexane, vortexed for 
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15 seconds, centrifuged at 4,000 xg for 10 minutes, and the supernatant was then 
transferred to a clean test tube.  An additional 3.0 mL of hexane was added to the serum, 
the contents were vortexed and centrifuged, and the supernatant was transferred to the 
test tube containing the previous extraction.  Nitrogen gas at 45 °C and 10 psi for 30 
minutes was used to evaporate the solvent from the serum extracts.  A final 0.5 mL of 
hexane was added, the contents were vortexed, and the HPLC analysis was repeated.  In 
spite of the concentrated sample, no oryzanol was detected. 
Serum Cholesterol 
In addition, a cholesterol assay was performed on the before and after serum 
samples.  The same enzymatic colorimetric method was followed as for the rat serum 
detailed in the serum analysis section previously.  
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CHAPTER 4 
RESULTS AND DISCUSSION 
Weight Gain, Final Weight, and Liver Weight 
 Final weight was not significantly different (P=0.2088) among the three oryzanol 
(RO, CO, DO) and two control diet groups (C, SH) (Figure 3, Table 2).  However, weight 
gain approached significance (P=0.0597) with the greatest variation between the SH and 
RO rats.  In general, all five groups showed a gradual increase in weight over the 11-
week feeding period with the exception of a dip at week 4 and a leveling off in the C, SH, 
and DO groups beginning at week 10.  Feed efficiency was significantly higher in 
animals fed rice bran oil (RO) versus the sham-operated (SH) control group.  Differences 
in feed efficiency among the remaining groups were not significant. 
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FIGURE 3  Average weekly weight by diet group.  Data points are means ± 
SEM. 
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These results are consistent with those reported by Edwards and Radcliffe (1994), 
where rats fed diets of either rice bran oil or corn oil for 28 days did not differ 
significantly with respect to final weight, weight gain, or feed intake.  Likewise, rat 
studies comparing rice bran oil to groundnut oil revealed similar consumption and weight 
gain between test groups (Sharma & Rukmini, 1986), even when rice bran oil feeds were 
supplemented with additional amounts of the unsaponifiable fraction (Sharma & 
Rukmini, 1987) or oryzanol (Seetharamaiah & Chandrasekhara, 1989).  Previous 
comparisons of feed intake and growth between groups of rats assigned to feeding 
regimens of rice bran oil versus safflower oil were also statistically indistinguishable 
(Radcliffe et al., 1997; Koba et al., 2000). 
In this research, liver weights were not statistically different among the 
experimental groups (Table 2).  Some studies have shown significant reduction in liver 
weights in animals consuming oryzanol (Seetharamaiah & Chandrasekhara, 1989; 1988).  
However, an experiment comparing rice bran oil to other edible oils (Sharma & Rukmini, 
1986), and another investigating the effects of unsaponifiables in rice bran oil (Sharma & 
Rukmini, 1987) did not find significant differences.  In summary, the weight gain, final 
weight, and liver weight results reported here were not surprising, as it was not expected 
that oryzanol would necessarily affect these outcomes.   
Balance Study 
Feed Intake 
 Although feed intake did not differ significantly among the three oryzanol- fed 
groups (P = 0.1451), animals assigned to the rice bran oil (RO) diet consumed more on 
 39 
average than other diet groups (Table 3, Table 5).  Perhaps the rats found the flavor or 
texture of this feed to be more palatable.   
TABLE 2 
Effect of test diets on total weight gain, final body weight, feed efficiency, and liver 
weight.1,2 
 
Diet Group Weight Gain (g/81 days) 
Final Weight 
(g) Feed Efficiency
3 Liver Weight (g) 
C (9) 39 ± 6.2 393 ± 13.7 2.9 ± 0.43a,b 9.941 ± 0.2978 
SH (10) 21 ± 9.7 366 ± 9.2 1.5 ± 0.68a 10.332 ± 0.3008 
RO (8) 60 ± 11.4 401 ± 11.8 4.2 ± 0.70b 10.226 ± 0.3243 
CO (8) 37 ± 11.8 382 ± 14.8 2.8 ± 0.81a,b 9.689 ± 0.5469 
DO (9) 50 ± 7.8 395 ± 7.2 3.5 ± 0.45a,b 9.865 ± 0.2985 
 
1Values are means ± SEM.  The number of animals in each group follows the diet 
group name in parentheses.  
 2Different letters within a column represent significant differences (P < 0.05). 
3Feed Efficiency is calculated as g of weight gained / 100 g of feed intake. 
 
 
Feed intake during the second stay in the metabolism cages (Period B) was 
significantly less for all diet groups both independently and combined when compared to 
the first stay (Period A) (Table 3, Table 5).  It was initially hypothesized that the larger 
sizes of the rats at the latter stage inhibited their access to feed in the confined 
metabolism cages.  However, a review of records for the entire study revealed that feed 
intake averaged across all groups declined steadily after week 5 of the feeding regimen.  
Similarly, between week 7 and the completion of the study, a decreasing trend occurred 
within each diet group.  The gradual increase in average weight of the rats over this same 
period, at least through the second collection period, leads to the conclusion that the drop 
in feed consumption for Period B as compared to Period A was due to increased feed 
efficiency in the maturing animals. 
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Oryzanol Intake 
 Oryzanol intake values were calculated based on actual oryzanol concentrations 
of the diet mixtures.  HPLC analysis of diet samples revealed a slightly lower percentage 
of oryzanol in the RO diet mixture (2.3 g/kg) versus the crystalline oryzanol (CO) and 
crystalline oryzanol dissolved in corn oil (DO) diets, which were both equivalent to the 
predicted concentration of 2.8 g/kg.  The HPLC analysis also revealed differences in 
chromatograph curve shapes between the crystalline form and the rice bran oil version 
(Appendix E).  Obviously, the decrease in feed intake associated with Period B translated 
to a decrease in the average oryzanol intake, as well (Table 3, Table 5).  However, 
significant differences were not found in oryzanol intake among the three oryzanol- fed 
groups. 
TABLE 3 
 Feed and oryzanol intake associated with fecal collection periods of oryzanol- fed rats.1,2 
 
Diet 
Group 
Batch 
Feed 
 Intake 
 (g/day) 
Oryzanol 
Intake (mg/day) 
RO (8) A 
B 
Both 
20 ± 0.9 
17 ± 1.0 
18 ± 0.7 
45.387 ± 2.0353 
39.137 ± 2.3416 
42.262 ± 1.7021 
CO (8)  A 
B 
Both 
18 ± 0.4 
15 ± 0.7 
17 ± 0.6 
51.862 ± 1.0890 
42.233 ± 1.9515 
47.047 ± 1.5933 
DO (9) A 
B 
Both 
18 ± 0.8 
15 ± 0.6 
17 ± 0.6 
50.379 ± 2.3361 
43.484 ± 1.5680 
46.931 ± 1.6005 
 
1Values are means ± SEM.  The number of animals in each group follows the diet 
group name in parentheses. 
2Significant differences are noted in Table 5. 
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Oryzanol Recovery 
Combining data from both fecal collection periods revealed that a significantly 
higher percentage of dietary oryzanol was recovered in the feces of animals fed the CO 
(41.9 ± 2.21) diet compared to both the RO (28.3 ± 3.54) and DO (27.8 ± 2.63) diets 
(Table 4, Table 5).  Analysis of data collected solely from Period A also resulted in 
significantly higher recovery percentages of dietary oryzanol in the fecal matter of the 
CO (44.6 ± 3.33) versus the RO (26.2 ± 5.26) and DO (26.0 ± 2.88) groups.  The trend 
was in the same direction for Period B data, but numbers were not significant.  No 
oryzanol was detected in the feces of C or SH rats which consumed oryzanol- free diets.  
Significant differences in data related to the oryzanol balance study are summarized in 
Table 5.  See Appendix F for examples of HPLC curves from each diet group. 
TABLE 4 
 
 Total weight of dry feces, amount of oryzanol detected in feces, and percentage of 
dietary oryzanol recovered in the feces.1 
 
Diet 
Group Batch Feces (g) 
Fecal Oryzanol 
(mg) 
% Oryzanol 
Recovered 
In Feces 
RO (8) A 
B 
Both 
1.220 ± 0.0940 
1.071 ± 0.1479 
1.146 ± 0.0868 
11.818 ± 2.3186 
11.643 ± 1.6122 
11.731 ± 1.3643 
26.2 ± 5.26 
30.4 ± 4.96 
28.3 ± 3.54 
CO (8)  A 
B 
Both 
1.365 ± 0.0593 
0.996 ± 0.0718 
1.180 ± 0.0636 
23.116 ± 1.7483 
16.536 ± 1.4123 
19.826 ± 1.3510 
44.6 ± 3.33 
39.2 ± 2.82 
41.9 ± 2.21 
DO (9) A 
B 
Both 
0.956 ± 0.1773 
0.784 ± 0.1410 
0.870 ± 0.1118 
13.383 ± 1.8682 
12.617 ± 1.7500 
13.000 ± 1.2452 
26.0 ± 2.88 
29.6 ± 4.50 
27.8 ± 2.63 
 
1Values are means ± SEM.  The number of animals in each group follows the diet 
group name in parentheses.  
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TABLE 5 
 
Significant effects of test diets on feed intake, oryzanol intake, feces, fecal oryzanol and 
percentage of dietary oryzanol recovered in the feces.1 
 
Diet 
Group Batch 
Feed 
Intake 
(g/day) 
Oryzanol 
Intake 
(mg/day) 
Feces 
(g) 
Fecal 
Oryzanol 
(mg) 
% 
Oryzanol 
Recovered 
In Feces 
 A vs B P < 0.05  P < 0.05 P < 0.05 P < 0.05 NS 
CO vs RO  NS NS NS P < 0.05 P < 0.05 
CO vs DO  NS NS NS P < 0.05 P < 0.05 
CO A vs B NS NS NS P < 0.05 NS 
CO vs RO A NS NS NS P < 0.05 P < 0.05 
CO vs DO A NS NS NS P < 0.05 P < 0.05 
 
1NS implies a non-significant result.  P < 0.05 implies significance. 
 
Only one previously published experiment measur ing fecal recovery of dietary 
oryzanol was located.  In 1983, Fujiwara et al. found oryzanol to be poorly absorbed.  
After injecting an oral dose of radioactively labeled crystalline oryzanol (at the C-3 
position of the ferulic acid), 84.5% of the radioactivity was recovered in the feces.  In a 
second experiment published in the same article, only 10 to 20% of oryzanol appeared to 
be metabolized in the intestine.  This would suggest that at least 64.5% of intact oryzanol 
was excreted in the feces.  This is much higher than the findings of this study.  Although 
the highest recovery rates were seen in the CO group collected during Period A, the 
average recovery rate was only 44.6%.  It is possible that a portion of oryzanol in the 
feces was bound up in lipid complexes rendering hexane incapable of complete 
extraction.  This occurrence would have resulted in average recovery values lower than 
the true mean.  Or perhaps, the percentage of oryzanol metabolized in the study by 
Fujiwara et al. was underestimated due to the small sample size of three.   
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An alternative way to view the results from the oryzanol balance study is to 
consider the percentage of dietary oryzanol not recovered in the feces.  This portion is 
assumed to have been either metabolized or absorbed, or both.  The percentage of dietary 
oryzanol not recovered in the feces was significantly higher for the RO and DO groups 
compared to the CO group (Figure 4).  This data supports our hypothesis that dissolving 
crystalline oryzanol in oil enhances its bioavailability. 
Again, we must consider the likelihood that hexane extraction of oryzanol in the feces 
was not complete.  It is possible that oryzanol in rice bran oil or dissolved in corn oil is 
less likely to be bound up in lipid complexes in the intestinal lumen than crystalline 
oryzanol.  This explanation could be tested by repeating the extraction with a 
chloroform:methanol mixture (Folch et al., 1957) and comparing the results to those from 
the hexane extraction. 
Rice Bran Oil and Corn Oil Analysis 
Although both the tocopherol-stripped corn oil and the high-oryzanol rice bran oil 
generated HPLC peaks with retention times between four and ten minutes, the pinnacle of 
the rice bran oil peak appeared at 7.354 minutes, while the highest point on the corn oil 
graph was not reached until 9.382 minutes.  Moreover, the area under the curve for a 
similar sample size was nearly 70-fold for the rice bran oil versus the corn oil.  Results 
from this qualitative test suggested that while some compounds other than oryzanol might 
have been quantified as oryzanol, the impact on recovery values would have been 
minimal.  Oryzanol was quantified during HPLC analysis of the feces, serum, and liver 
using peaks with retention times between approximately 5.5 and 11.5 minutes.   
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 FIGURE 4  Percentage of dietary oryzanol not recovered in the feces by diet  
group and batch.  Values reflect means.  Error bars represent SEM. 
   
Serum Cholesterol 
Enzymatic Colorimetric Assay 
 Serum from the five experimental groups were analyzed for total cholesterol by 
enzymatic colorimetric assay to compare the effects of the test diets.  Total cholesterol 
levels were highest in the RO group followed in decreasing order by the DO, CO, C and 
SH groups (Table 5).  However, differences between the test groups were not statistically 
significant.  
 Since the sham-operated (SH) rats did not have their ovaries removed, it was 
expected that the cholesterol levels in this group would be lower than the ovariectomized 
controls (C).  The removal of ovaries and cessation of menses have both been associated 
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TABLE 6 
Comparison of total cholesterol values by diet group obtained from enzymatic 
colorimetric assay and GCMS using hexane or chloroform:methanol extraction.1 
 
GCMS  Enzymatic Colorimetric Assay Hexane Folch Method 
Diet 
Group 
n Cholesterol 
(mg/dL) 
n Cholesterol 
(mg/dL) 
n Cholesterol 
(mg/dL) 
C 9 119.5 ± 5.02 3 16.4 ± 14.5 3 22.9 ± 3.44 
SH 10 98.1 ± 5.79 2 30.8 ± 5.7 3 15.8 ± 6.75 
RO 8 135.0 ± 16.57 4 14.0 ± 7.6 3 22.8 ± 3.23 
CO 8 123.8 ± 10.24 3 6.0 ± 5.8 3 20.4 ± 2.40 
DO 9 128.1 ± 13.75 5 18.5 ± 7.6 3 34.9 ± 11.5 
 
1Values are means ± SEM. 
  
with higher total cholesterol levels due to the drop in estrogen production (Davidson, 
Maki, Karp, & Ingram, 2002).  No previous studies were found that specifically 
examined differences in cholesterol between ovariectomized rats fed oryzanol and non-
ovariectomized rats sustained on oryzanol- free diets.  Therefore, no prediction was made 
as to where the SH group would fall with respect to the ovariectomized oryzanol- fed 
groups. 
However, the trend among the ovariectomized control and oryzanol diet groups 
was the exact reverse of what was hypothesized based on the review of literature.  
Researchers reported lower total cholesterol levels in rats fed oryzanol compared to 
controls (Seetharamaiah & Chandrasekhara, 1988, 1989, 1993).  Likewise, Yoshino et al. 
(1989) reported reduced total serum cholesterol in hyperlipidemic patients consuming 
300 mg/day of gamma-oryzanol. 
In each of these studies, however, diets were enriched with cholesterol.  Previous 
research has shown a substantial increase in total serum cholesterol of rats sustained on a 
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cholesterol-enriched diet when compared to cholesterol- free diet groups.  Sharma and 
Rukmini (1986) found an increase of over 100 mg/dL in rats fed a diet supplemented 
with 0.1% cholesterol and 0.05% cholic acid.  These researchers also found that a 
cholesterol-enriched diet was required to see significant decreases in serum lipid levels of 
animals sustained on a diet containing rice bran oil versus groundnut oil.  In a study using 
cholesterol- free diets for all test groups, serum cholesterol levels between rats fed rice 
bran oil versus corn oil did not differ (Edwards & Radcliffe, 1994).  Therefore, it was 
theorized post hoc in our study, that a diet containing cholesterol might be required to 
detect a cholesterol- lowering effect of oryzanol in rats.  Similarly, use of oryzanol to 
lower cholesterol in humans may prove to be more effective for those not able to comply 
with a very low-cholesterol diet on a long-term basis. 
A second plausible explanation for this reversed trend is that the Infinity 
cholesterol reagent used in the colorimetric assays was not specific for cholesterol.  In 
other words, the oxidase that reacts with cholesterol to form hydrogen peroxide may also 
be capable of a similar reaction with a phytosterol such as oryzanol.  It is the hydrogen 
peroxide product that is ultimately quantified and used to calculate the total cholesterol 
concentration in the serum sample. 
To test this theory, a small amount of high-oryzanol rice bran oil was dropped 
into a glass test tube containing the cholesterol reagent.  Upon vortexing, a cloudy, pink 
mixture formed.  This procedure was repeated using each of the following:  stripped corn 
oil, a vortexed mixture of stripped corn oil and crystalline oryzanol, and crystalline 
oryzanol alone.  All three turned a pale shade of pink.  Therefore, the hypothesis that the 
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cholesterol levels in the oryzanol- fed rats were erroneously inflated due to higher levels 
of phytosterols in the serum was not rejected. 
GCMS 
Hexane Extraction.  Results from GCMS analysis of serum extracts prepared by 
hexane extraction were highly variable.  This outcome suggested that hexane was not 
useful as an extraction solvent for this medium.  The procedure was abandoned prior to 
analysis of the entire data set.  It is not likely that the values obtained by this method in 
any way reflect even true relative cholesterol levels.  However, the relationship was as 
follows:  CO < RO < C < DO < SH.  
Chloroform:Methanol Extraction.  As with results from the enzymatic 
colorimetric assays, lowest total cholesterol values were associated with the SH group 
following the chloroform:methanol extraction of Folch et al. (1957).  Serum availability 
limited analysis to only three samples from each of the five test groups.  Although small 
sample size and variability prevented statistical significance, values from the remaining 
groups had the following relation:  CO < RO < C < DO. 
Results from this GCMS analysis were substantially lower than those obtained 
using the enzymatic colorimetric assay.  Cholesterol values obtained by GCMS ranged 
from only 16% of the cholesterol values resulting from the enzymatic assay in the SH and 
CO groups to 27% for the DO group.  Averaging all cholesterol values from both sets of 
analyses resulted in GCMS values at only 19% of the enzymatic assay.  This suggests 
that although the Folch method is advantageous over extraction with hexane, further 
perfection of the extraction and/or subsequent GCMS procedure is required. 
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Oryzanol in Serum 
GCMS analysis following hexane extraction of RO serum compared to that of a 
control rat did not reveal the presence of oryzanol.  Likewise, no oryzanol was detected 
in the HPLC analysis of serum from the human pilot study (Appendix G).  If oryzanol is 
present in the serum, it is likely that it is transported through the blood like cholesterol as 
a component of lipoproteins.  Therefore, in light of the results from the cholesterol 
analysis, it is possible that hexane was not an optimal extraction reagent for serum 
oryzanol. 
It would not be surprising, however, if oryzanol is in fact poorly absorbed.  As 
mentioned above, Fujiwara et al. (1983) reported minimal absorption of oryzanol.  They 
noted an 84.5% fecal recovery rate of the radioactivity from an oral dose of labeled 
oryzanol.  In addition, 9.8% of the radioactivity was recovered in the urine, but no 
oryzanol was detected in the radioactive fraction implying that the compound being 
quantified was likely only its ferulate metabolite.   
These researchers also reported radioactivity in the blood, but it was not 
determined whether the detected compound was intact oryzanol or ferulic acid.  Although 
it is not likely that oryzanol is present in the blood, further analysis following a superior 
extraction procedure is necessary for an unequivocal conclusion.  Additionally, it would 
be worthwhile to investigate whether or not oryzanol metabolites are present in serum.  It 
is possible that metabolites were not detected in this experiment due to GCMS retention 
times of these compounds exceeding the studied range of zero to 65 minutes. 
Oryzanol in Liver 
 As with analysis of the serum, HPLC and GCMS analysis of hexane extracts of 
homogenized liver did not reveal oryzanol (Appendix H).  Again, it is probable that 
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hexane was not effective at extracting lipids from the tissue.  However, it seems likely 
that significant uptake of intact oryzanol into the liver would have been detected.  
Considering these results and previous studies that have suggested poor absorption of 
oryzanol and phytosterols, it is likely that the oryzanol content of liver is either none or 
very small. 
Fate of Dietary Oryzanol 
Averaged over both collection periods, the percentage of dietary oryzanol not 
recovered in the feces ranged from 58.1% in the CO group to 72.2% in the DO group.  
The explanation for the disappearance of oryzanol is uncertain.  One possible fate of 
dietary oryzanol is absorption into the epithelial cells of the small intestine as an intact 
compound.  Due to its insolubility in an aqueous solution, it is predicted that oryzanol 
would be incorporated into micelles in the intestinal lumen with the aid of bile.  The 
micelle formation allows non-polar substances to be transported to the brush border of 
the mucosal cells for intestinal absorption (Mayes, 2000).  Once inside the intestinal cells, 
it is reasonable that oryzanol would be incorporated into chylomicrons for transport 
through the lymph in a similar manner to that of dietary cholesterol.  In refute of this 
theory, Fujiwara et al. (1983) reported that oral injections of gamma-oryzanol resulted in 
entry of the intact compound into the systemic system via the portal vein.  
Although oryzanol may be absorbed as an intact compound, it is probable that at 
least some percentage of dietary oryzanol is metabolized prior to entering the systemic 
system.  Esterases present in the mucosal cells of the small intestine and in the luminal 
microflora of the large intestine are likely capable of cleaving the ester bond connecting 
the ferulic acid to the sterol portion of the compound (Andreason, Kroon, Williamson,
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& Garcia-Conesa, 2001).  The expected metabolites of oryzanol are ferulic acid and the 
various triterpene alcohols.  The three most abundant triterpene alcohols in oryzanol are 
cycloartenol, 24-methylenecycloartanol, and campesterol (Xu & Godber, 1999). 
Adam et al. (2002) investigated the absorption of ferulic acid in rats using an 
intestinal perfusion model.  Absorption rates of perfused ferulic acid were directly 
proportional to the concentration of the perfusion.  The authors suggested, therefore, that 
ferulic acid is absorbed by passive diffusion or by facilitated transport.  In a feeding study 
published in the same work, Adam et al. reported a 50% absorption rate in rats of ferulic 
acid added to a semi-purified diet.  High recovery of ferulic acid in urine and 
undetectable plasma concentrations within 18 hours of a meal was interpreted to mean 
that ferulic acid is readily and completely eliminated in urine. 
There is some evidence that cycloartenol is absorbed and stored in the liver 
(Rukmini & Raghuram, 1991).  Ikeda et al. (1985) reported cycloartenol absorption four 
times that of ß-sitosterol in rats.  A literature search utilizing Web of Knowledge on 
February 13, 2003, did not produce any references concerning intestinal absorption of 24-
methylenecycloartenol.  The absorption rate of campesterol has been estimated near 10% 
in humans (Heinemann, Axtmann, & Von Bergmann, 1993).  In rats fed a diet containing 
unsaponifiables from rice bran oil, Nagao et al. (2001) reported double concentrations of 
serum campesterol versus levels in those not consuming the unsaponifiables.  Triterpene 
alcohols are similar to cholesterol in structure and may be incorporated into the 
chylomicron surface as is free cholesterol.  Evaluation of serum and liver for ferulic acid 
and these triterpene alcohols in future studies would provide additional insight into 
oryzanol metabolism. 
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Yet another explanation for dietary oryzanol not detected in the feces is that 
neither oryzanol nor its metabolites are absorbed.  Rather, oryzanol is metabolized in the 
gut and the products are then excreted.  It is well accepted that the absorption of 
phytosterols is limited relative to cholesterol (Moghadasian, 2000).  Therefore, although 
partial absorption of these metabolites is possible, a high excretion rate is likely.  Further 
research could explore the extent to which oryzanol metabolites are excreted. 
Mode of Action of Oryzanol as Hypolipidemic Agent 
Serum cholesterol concentrations did not differ significantly between 
experimental groups in this study.  However, a substantial number of previous studies 
have attributed decreases in serum and liver cholesterol to intake of rice bran and its 
unsaponifiable fraction, particularly oryzanol.  Several theories exist regarding modes of 
action of cholesterol- lowering agents, including:  (1) Interrupting a step in the 
biochemical synthesis of de novo cholesterol.  Statins, the most effective cholesterol-
lowering group of pharmaceuticals currently on the market, work in this manner by 
inhibiting the HMG-CoA reductase enzyme (Mayes, 2000).  (2) Attenuating absorption 
of dietary cholesterol.  Due to their cholesterol- like structure, some phytosterols, 
especially saturated compounds such as sitostanol, are thought to work this way via 
competitive absorption (Jones & Kubow, 1999).  (3) Inhibiting enterohepatic circulation 
of bile acids by limiting reabsorption in the ileum.  Bile acid excreted in the feces 
necessitates liver production of new bile which requires cholesterol as a substrate 
(Grundy, 1986).  In turn, LDL receptors are up-regulated as a result of diminished hepatic 
cholesterol stores.  Cholesterol- lowering drugs known as bile acid sequestrants utilize this 
mode of action.   
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If it is true that a cholesterol-enriched diet is required to see the hypolipidemic 
effects of oryzanol, then one would conclude that oryzanol works to lower cholesterol 
levels by inhibiting absorption of dietary cholesterol rather than by controlling the 
synthesis of de novo cholesterol.  This theory is in agreement with Nagao et al. (2001) 
whose research team reported that neither rice bran oil nor its unsaponifiable fraction 
alone significantly altered messenger RNA for HMG-CoA reductase, LDL receptor, or 
cholesterol 7a-hydroxylase.  They concluded that unsaponifiables from rice bran oil 
inhibited intestinal absorption of dietary cholesterol.  The same conclusion was reached 
by Rong et al. (1997) who studied the effects of oryzanol on cholesterol levels in 
hamsters.  Kahlon et al. (1996) inferred that the unsaponifiable content of rice bran oil 
exerted its hypolipidemic action by increasing both fecal fat and neutral sterol excretion.  
Sharma and Rukmini (1986) previously hypothesized that increased bile acid excretion in 
rats consuming rice bran oil was due to unsaponifiables creating an unsuitable 
environment for micelle formation or inhibiting reabsorption of bile acids. 
It is possible that intact oryzanol is responsible for inhibition of dietary 
cholesterol absorption and/or increased excretion of bile acids.  However, due to the 
likelihood that esterases in the gut are capable of cleaving the ester bond, it is possible 
that the cholesterol- lowering effect of oryzanol can be attributed in part to its metabolites.  
Ferulic acid alone has been shown to lower serum LDL in rats fed a high-cholesterol diet 
(Seetharamaiah & Chandrasekhara, 1993).  Kiribuchi, Miura, & Tokuda (1983) reported 
a synergistic cholesterol- lowering effect of cycloartenol and 24-methylenecycloartanol in 
combination with soysterol fed to rats.  Mildly hypocholesterolemic men consuming a 
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phytosterol mixture that was 27% campesterol for four weeks experienced a significant 
drop in serum cholesterol levels (Matvienko et al., 2002). 
Conclusions  
This study suggests that more than 50% of dietary oryzanol is either absorbed or 
metabolized in the gut.  Some metabolism of oryzanol is probable due to the presence of 
esterases in the intestinal lumen and mucosal cells.  It remains uncertain what percentage 
of oryzanol or its metabolites are absorbed.  Previous research suggests that oryzanol, 
ferulic acid, and at least some of the plant sterol components of oryzanol are absorbed to 
a limited degree.  Regardless, dissolving crystalline oryzanol in oil appears to enhance 
bioavailability to the extent that it is comparable to high-oryzanol rice bran oil.   
Assuming that oryzanol does possess hypolipidemic qualities, its mechanism of 
action is of interest.  Oryzanol did not significantly affect serum cholesterol levels in this 
study.  Therefore, it is likely that dietary cholesterol is necessary for the hypolipidemic 
benefits of oryzanol to be realized in rats.  This suggests that oryzanol and/or its 
metabolites work to lower cholesterol levels by inhibiting absorption of dietary 
cholesterol.  In humans, oryzanol as a pharmaceutical may not be capable of improving 
cholesterol levels beyond the degree that would be obtainable by adhering to a very low 
cholesterol diet.  However, given the high cholesterol content of the typical Western diet, 
further research regarding oryzanol as a cholesterol- lowering agent is certainly justified.  
The chloroform:methanol method modified from Folch et al. (1957) appeared to 
be superior to hexane ; however, the discrepancy between cholesterol values obtained via 
enzymatic colorimetric assay and GCMS indicates a shortcoming.  Although the 
extraction methods used in this study appear to have some degree of fallibility, it is 
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reasonable to conclude that the presence of intact oryzanol is minimal or non-existent in 
serum and liver. 
Future Directions  
Hexane may have been a poor extraction reagent in this balance study due to the 
possibility that some fecal oryzanol is bound up in lipid structures.  Therefore, it is 
suggested that remaining fecal samples be extracted using a chloroform:methanol method 
(Folch et al., 1957).  Oryzanol recovery quantification via HPLC could be repeated in 
order to validate or dispute the results reported here. 
Although oryzanol’s mode of action remains uncertain, growing evidence 
supports the theory that oryzanol lowers cholesterol levels by (1) inhibiting dietary 
cholesterol absorption and (2) increasing excretion of bile acids.  Quantifying bile acids 
and neutral sterols would indicate whether excretion rates are higher for the more 
bioavailable oil forms of oryzanol.  Measuring the expected metabolites of oryzanol in 
feces and urine, such as ferulic acid, cycloartenol, 24-methylenecycloartanol, and 
campesterol from rats fed the three oryzanol diets would provide information concerning 
the rate at which oryzanol is metabolized in the gut and whether the rate varies between 
oil and crystalline forms.  Results would be more meaningful if the experiment was 
repeated using a high cholesterol diet and significant differences in cholesterol levels 
were discovered. 
A review of the literature suggests that the chloroform:methanol solvent (Folch et 
al., 1957) is an appropriate reagent for extracting lipids from serum and liver.  However, 
results obtained in this study were highly variable.  It would be worthwhile to perfect the 
extraction methodology in order to analyze liver and serum cholesterol via GCMS in 
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future studies.  Rats should be fasted prior to blood draw so that total, LDL, and HDL 
cholesterol values can be obtained.  Oryzanol concentrations in liver, adipose tissue, and 
urine could be quantified using the perfected extraction procedure as well. 
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APPENDIX A 
FORMULAS 
Calculation for oryzanol concentration in test diets and feces 
SS
PA
X
*4107260
= , where X is the concentration value in mg/g units, PA is the 
area under the HPLC curve for the oryzanol peak, and SS is the sample size in g. 
 
Calculation for serum cholesterol levels obtained by enzymatic colorimetric assay 
200´=
CAL
AAV
TC  mg/dL, where TC is the total cholesterol value in mg/dL, AAV 
is average of the colorimetric absorption values for the prepared serum sample, and CAL 
is the colorimetric absorption value of the calibrator.   
 
Calculation for a-cholestane standard in serum samples analyzed by GCMS 
000,000,30
8.1221+
=
PA
X , where X is the concentration value in µg/µL units and PA is 
the area under the GCMS curve for the a-cholestane  peak. 
 
Calculation for serum cholesterol analyzed by GCMS 
000,000,4
2012+
=
PA
X , where X is the concentration value in µg/µL units and PA is the 
area under the GCMS curve for the cholesterol  peak. 
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Standard curves for a-cholestane and cholesterol 
Cholestane y = 3E+07x - 1221.8
R
2
 = 0.8952
0
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CHOL y = 4E+06x - 2012
R
2
 = 0.9778
0
100000
200000
300000
400000
500000
600000
700000
0.01 0.02 0.03 0.04 0.05
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APPENDIX B 
 
HPLC OF LIVER SAMPLES PERFORMED DURING METHODOLOGY 
DEVELOPMENT 
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Test Liver 2 – Spiked with cholesterol
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APPENDIX C 
 
DAILY RICE BRAN OIL INTAKE FOR HUMAN PILOT STUDY 
 
The following calculations are used to estimate a daily intake amount of rice bran 
oil for a 70 kg person that is comparable to the RO diet based on the percentage of total 
calories that are contributed by high-oryzanol rice bran oil. 
RO Diet 
Rice bran oil content of RO test diet:  40 g/kg 
Approximate calorie content of 1 g of rice bran oil:  9 kcal  
Caloric content of high-oryzanol rice bran oil in RO diet:  40 × 9 = 360 kcal/kg 
Total caloric content of RO diet:  3742 kcal/kg diet 
Percent calories of rice bran oil in RO diet:  (360 / 3742) × 100 = 9.6% 
Estimate for Human Diet 
Caloric amount for 70 kg person on 2,000 kcal diet:  2000 × 0.096 = 192 kcal 
Quantity for 70 kg person on 2,000 kcal diet:  192 / 9 = 21.33 g/day 
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APPENDIX D 
MUFFIN RECIPE FOR HUMAN PILOT STUDY 
Combine and allow to cool: 
3/8 c. 10-grain cereal 
¾ c. boiling water 
½ tsp. instant decaffeinated coffee 
 
In medium bowl, mix well: 
1 egg white 
1/8 c. light brown sugar, packed 
¼ c. high-oryzanol rice bran oil (7% oryzanol) 
10-grain cereal mixture from above 
½ tsp. vanilla extract  
1/3 c. chopped dates 
1 Tbl. sunflower seeds 
2 Tbl. semi-sweet chocolate chips 
 
In small bow, combine well: 
¾ c. cake flour, unsifted 
1 tsp. baking powder 
¼ tsp. baking soda 
¼ tsp. salt 
 
Fold wet and dry mixtures together until just moistened.  Line six-cup muffin tin with 
paper cups that have been coated with non-stick cooking spray.  Divide batter evenly 
among muffin cups.  Bake at 400°F for 20-25 minutes. 
 
Yield:  6 muffins. 
 
Adapted from Twelve Grain Muffins, 
www.bicyclesource.com/body/nutrition/muffins/twelve-grain-muffin.html. 
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APPENDIX E 
 
HPLC OF DIET SAMPLES 
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CO Diet Sample 
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APPENDIX F 
 
HPLC OF FECAL SAMPLE FROM EACH DIET GROUP 
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APPENDIX G 
 
HPLC OF HUMAN SERUM TO DETECT ORYZANOL 
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0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00
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APPENDIX H 
 
HPLC OF LIVER SAMPLE FROM EACH DIET GROUP 
 
 
m
V
0 .00
10.00
20.00
30.00
40.00
50.00
60.00
70.00
Minutes
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00
 
C7 
 
 
 
m
V
0.00
20.00
40.00
60.00
80.00
100.00
120.00
140.00
160.00
180.00
Minutes
0.00 2.00 4.00 6.00 8.00 10.00 12.00 14.00
 
SH 6 
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m
V
0 .00
10.00
20.00
30.00
40.00
50.00
60.00
70.00
80.00
90.00
Minutes
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00
 
RO 2 
 
 
 
m
V
0.00
10.00
20.00
30.00
40.00
50.00
60.00
70.00
80.00
90.00
100.00
Minutes
0.00 2.00 4.00 6.00 8.00 10.00 12.00 14.00
 
CO 5 
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m
V
0 .00
10.00
20.00
30.00
40.00
50.00
60.00
70.00
80.00
Minutes
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00
 
DO 9 
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